(VCBeat) Mar. 12, 2021 -- Recently, Shanghai Novamab Biopharmaceuticals Co., Ltd. ("Novamab"), a leading company in the R&D of innovative nanobody drugs, announced the completion of Series A financing of RMB 100 million, led by Tianhui Capital, with participation from TigerYeah Capital and Fuho Capital. Haoyue Capital served as the exclusive financial adviser for this round of financing. 

The funds are earmarked for the development of IND and clinical studies for inhaled nanobody drugs for asthma treatment, as well as several other projects in the pipeline.

Novamab was established in Shanghai International Medical Zone in 2017 and was recognized as a national high-tech enterprise in 2020. It has an R&D and production base of more than 2,500 square meters and a unique camel herding base. Novamab has independently developed the five core technology platform based on nanobodies: the nanobody screening platform, the Pichi CMC technology development platform, the inhaled macromolecular drug R&D platform, the long-acting nanobody platform and the bi-specific nanobody platform. Each platform has unique advantages in the industry, which is able to quickly screen out with active nanobody drugs and realize rapid industrialization.

Dr. Wan Yakun, the founder of Novamab, is a pioneer in the field of nanobodies in China. He once served as the director of the first domestic nanobody research center and applied for more than 40 patents related to nanobodies.

Tianhui Capital is not only an investor but a navigator deeply engaged in the medical and healthcare industry. The core team of the company has been worked in investment management for nearly 20 years. With the investment strategy of "professionalizing, investing in the early stage, platformization and internationalization", Tianhui Capital focuses on the fields of precision medicine, high-end medical devices, innovative drugs and new treatments.

Founded in 2014, TigerYeah Capital is dedicated to build itself as a famous brand in the healthcare investment field and become a top-tier investment firm. TigerYeah Capital focuses on early and growing equity investment in healthcare, especially in the field of the Medical Device, Health Food, CRO, and Health Services. By leveraging Tigermed solid platform and TigerYeah's abundant industrial resources, TigerYeah Capital provides comprehensive post-investment services for entrepreneurs.